间充质基质细胞：急性移植物抗宿主病的机制是什么？
Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease?
作者信息
Dunavin Neil, Dias Ajoy, Li Meizhang, McGuirk Joseph
机构信息
Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, 2330 Shawnee Mission Pkwy., Westwood, KS 66205, USA.
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160, USA.
出版信息
Biomedicines. 2017 Jul 1;5(3):39. doi: 10.3390/biomedicines5030039.
Abstract
After more than a decade of preclinical and clinical development, therapeutic infusion of mesenchymal stromal cells is now a leading investigational strategy for the treatment of acute graft-versus-host disease (GVHD). While their clinical use continues to expand, it is still unknown which of their immunomodulatory properties contributes most to their therapeutic activity. Herein we describe the proposed mechanisms, focusing on the inhibitory activity of mesenchymal stromal cells (MSCs) at immunologic checkpoints. A deeper understanding of the mechanism of action will allow us to design more effective treatment strategies.
摘要
经过十多年的临床前和临床开发，间充质基质细胞的治疗性输注现已成为治疗急性移植物抗宿主病（GVHD）的主要研究策略。尽管它们的临床应用在不断扩大，但仍不清楚它们的哪种免疫调节特性对其治疗活性贡献最大。在此，我们描述了所提出的机制，重点是间充质基质细胞（MSCs）在免疫检查点的抑制活性。对作用机制的更深入理解将使我们能够设计出更有效的治疗策略。
相似文献
1
Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease?间充质基质细胞：急性移植物抗宿主病的机制是什么？
Biomedicines. 2017 Jul 1;5(3):39. doi: 10.3390/biomedicines5030039.
2
Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.在小鼠急性移植物抗宿主病模型中，使用间充质干细胞和调节性T细胞的联合细胞疗法可提供一种协同免疫调节作用，该作用与TH1/TH2和Th17/Treg细胞的相互调节相关。
Cell Transplant. 2014 Apr;23(6):703-14. doi: 10.3727/096368913X664577. Epub 2013 Feb 26.
3
CCR7 guides migration of mesenchymal stem cell to secondary lymphoid organs: a novel approach to separate GvHD from GvL effect.CCR7引导间充质干细胞迁移至二级淋巴器官：一种区分移植物抗宿主病与移植物抗白血病效应的新方法。
Stem Cells. 2014 Jul;32(7):1890-903. doi: 10.1002/stem.1656.
4
Clinical Use of Mesenchymal Stromal Cells in the Treatment of Acute Graft-versus-Host Disease.间充质基质细胞在急性移植物抗宿主病治疗中的临床应用
Transfus Med Hemother. 2019 Feb;46(1):27-34. doi: 10.1159/000496809. Epub 2019 Feb 4.
5
Remestemcel-L for the treatment of graft versus host disease.用于治疗移植物抗宿主病的Remestemcel-L
Expert Rev Clin Immunol. 2017 Jan;13(1):43-56. doi: 10.1080/1744666X.2016.1208086. Epub 2016 Jul 29.
6
[Mesenchymal stem cells for treatment of graft-versus-host disease].[间充质干细胞用于治疗移植物抗宿主病]
Rinsho Ketsueki. 2017;58(12):2440-2449. doi: 10.11406/rinketsu.58.2440.
7
Therapeutic efficacy of cord blood-derived mesenchymal stromal cells for the prevention of acute graft-versus-host disease in a xenogenic mouse model.脐带来源间充质基质细胞预防异种鼠移植物抗宿主病的疗效。
Stem Cells Dev. 2012 Jul 1;21(10):1616-26. doi: 10.1089/scd.2011.0413. Epub 2011 Oct 21.
8
Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation.异体造血干细胞移植后接受第三方间充质基质细胞治疗的患者细胞免疫组分的改变。
Stem Cells. 2013 Aug;31(8):1715-25. doi: 10.1002/stem.1386.
9
[Ressarch Advances of Prevantive and Therapeatic Effect of Mesenchymal Stromal Cells on Graft-Versus-Host Disease--Review].[间充质基质细胞对移植物抗宿主病预防和治疗作用的研究进展——综述]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Feb;27(1):283-287. doi: 10.7534/j.issn.1009-2137.2019.01.046.
10
A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD.间充质基质细胞衍生的外泌体在预防移植物抗宿主病中的免疫调节作用。
J Hematol Oncol. 2018 Dec 7;11(1):135. doi: 10.1186/s13045-018-0680-7.
引用本文的文献
1
A review of nanomaterials in osteoarthritis treatment and immune modulation.纳米材料在骨关节炎治疗与免疫调节中的综述。
Regen Biomater. 2025 Jun 4;12:rbaf048. doi: 10.1093/rb/rbaf048. eCollection 2025.
2
Concurrent hypoxia and apoptosis imparts immune programming potential in mesenchymal stem cells: Lesson from acute graft-versus-host-disease model.同时存在的缺氧和细胞凋亡赋予间充质干细胞免疫编程潜能：来自急性移植物抗宿主病模型的启示。
Stem Cell Res Ther. 2024 Oct 29;15(1):381. doi: 10.1186/s13287-024-03947-2.
3
Advances in Stem Cell-Based Therapies in the Treatment of Osteoarthritis.基于干细胞的治疗方法在治疗骨关节炎方面的进展。
Int J Mol Sci. 2023 Dec 28;25(1):394. doi: 10.3390/ijms25010394.
4
Hypoxia and inflammatory factor preconditioning enhances the immunosuppressive properties of human umbilical cord mesenchymal stem cells.缺氧和炎症因子预处理增强人脐带间充质干细胞的免疫抑制特性。
World J Stem Cells. 2023 Nov 26;15(11):999-1016. doi: 10.4252/wjsc.v15.i11.999.
5
Facing the Challenges in the COVID-19 Pandemic Era: From Standard Treatments to the Umbilical Cord-Derived Mesenchymal Stromal Cells as a New Therapeutic Strategy.应对新冠疫情时代的挑战：从标准治疗到脐带间充质干细胞的新治疗策略。
Cells. 2023 Jun 19;12(12):1664. doi: 10.3390/cells12121664.
6
Non-clinical assessment of safety, biodistribution and tumorigenicity of human mesenchymal stromal cells.人间充质基质细胞安全性、生物分布及致瘤性的非临床评估
Toxicol Rep. 2021 Nov 29;8:1960-1969. doi: 10.1016/j.toxrep.2021.11.016. eCollection 2021.
7
LPS-Macrophages Alleviate the Outcome of Graft--Host Disease Without Aggravating Lymphoma Growth in Mice.脂多糖-巨噬细胞减轻移植物抗宿主病而不加重小鼠淋巴瘤生长。
Front Immunol. 2021 Aug 3;12:670776. doi: 10.3389/fimmu.2021.670776. eCollection 2021.
8
Mesenchymal stem cell exosome-derived miR-223 alleviates acute graft-versus-host disease via reducing the migration of donor T cells.间充质干细胞外泌体来源的 miR-223 通过减少供体 T 细胞的迁移来缓解急性移植物抗宿主病。
Stem Cell Res Ther. 2021 Feb 26;12(1):153. doi: 10.1186/s13287-021-02159-2.
9
Interactions Between Allogeneic Mesenchymal Stromal Cells and the Recipient Immune System: A Comparative Review With Relevance to Equine Outcomes.异基因间充质基质细胞与受体免疫系统的相互作用：与马的研究结果相关的比较性综述
Front Vet Sci. 2021 Jan 13;7:617647. doi: 10.3389/fvets.2020.617647. eCollection 2020.
10
COVID-19 and graft-versus-host disease: a tale of two diseases (and why age matters).COVID-19 与移植物抗宿主病：两种疾病的故事（以及年龄为何重要）。
Lab Invest. 2021 Mar;101(3):274-279. doi: 10.1038/s41374-020-00520-2. Epub 2020 Dec 9.
本文引用的文献
1
Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFNγ priming.通过γ干扰素预处理可纠正复制性衰老间充质基质细胞的免疫功能障碍。
Blood Adv. 2017 Apr 25;1(11):628-643. doi: 10.1182/bloodadvances.2017006205.
2
The Perfect Transplant.完美移植
Biol Blood Marrow Transplant. 2017 Jul;23(7):1044-1045. doi: 10.1016/j.bbmt.2017.05.010. Epub 2017 May 11.
3
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.异基因造血细胞移植后复发淋巴瘤的程序性死亡受体-1阻断治疗：缓解率高但移植物抗宿主病频繁。
Blood. 2017 Jul 13;130(2):221-228. doi: 10.1182/blood-2017-01-761346. Epub 2017 May 3.
4
Differential expression of cell cycle and WNT pathway-related genes accounts for differences in the growth and differentiation potential of Wharton's jelly and bone marrow-derived mesenchymal stem cells.细胞周期和WNT信号通路相关基因的差异表达导致了脐带来源间充质干细胞与骨髓来源间充质干细胞在生长和分化潜能上的差异。
Stem Cell Res Ther. 2017 Apr 26;8(1):102. doi: 10.1186/s13287-017-0555-9.
5
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.胞外核苷酸酶CD39和CD73：新型检查点抑制剂靶点。
Immunol Rev. 2017 Mar;276(1):121-144. doi: 10.1111/imr.12528.
6
Human Mesenchymal Stem Cell-Educated Macrophages Are a Distinct High IL-6-Producing Subset that Confer Protection in Graft-versus-Host-Disease and Radiation Injury Models.人骨髓间充质干细胞诱导的巨噬细胞是一个独特的高白细胞介素-6产生亚群，在移植物抗宿主病和辐射损伤模型中具有保护作用。
Biol Blood Marrow Transplant. 2017 Jun;23(6):897-905. doi: 10.1016/j.bbmt.2017.02.018. Epub 2017 Feb 28.
7
A Good Manufacturing Practice-grade standard protocol for exclusively human mesenchymal stromal cell-derived extracellular vesicles.一种专门针对人源间充质基质细胞衍生的细胞外囊泡的药品生产质量管理规范级标准方案。
Cytotherapy. 2017 Apr;19(4):458-472. doi: 10.1016/j.jcyt.2017.01.001. Epub 2017 Feb 7.
8
Extracellular Vesicle-Shuttled mRNA in Mesenchymal Stem Cell Communication.间充质干细胞通讯中细胞外囊泡穿梭的信使核糖核酸
Stem Cells. 2017 Apr;35(4):1093-1105. doi: 10.1002/stem.2557. Epub 2017 Feb 5.
9
Brief Report: Proteasomal Indoleamine 2,3-Dioxygenase Degradation Reduces the Immunosuppressive Potential of Clinical Grade-Mesenchymal Stromal Cells Undergoing Replicative Senescence.简报：蛋白酶体吲哚胺 2,3-双加氧酶降解降低了经历复制性衰老的临床级间充质基质细胞的免疫抑制潜力。
Stem Cells. 2017 May;35(5):1431-1436. doi: 10.1002/stem.2580. Epub 2017 Feb 23.
10
The Stromal Intervention: Regulation of Immunity and Inflammation at the Epithelial-Mesenchymal Barrier.基质干预：上皮-间充质屏障处免疫和炎症的调节。
Cell. 2017 Jan 26;168(3):362-375. doi: 10.1016/j.cell.2016.11.040.
Zotero 插件